Surging Prevalence of Hydrocephalus to Drive US Hydrocephalus Shunts Market

According to our new research study on “US Hydrocephalus Shunts Market Forecast to 2030 – Country Analysis – by Product, Type, Age Group, End User,” the US Hydrocephalus Shunts market size is expected to reach US$ 146.24 million by 2030 from US$ 109.61 million in 2022. The market is estimated to grow at a CAGR of 3.7% from 2022 to 2030. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the hydrocephalus shunts market.

Shunt, the surgical insertion of a drainage system, is the most common remedy for hydrocephalus. It drains extra cerebrospinal fluid from the brain and directs it to another body part, such as the abdomen, where it can be more easily absorbed. A shunt consists of a long and flexible tube with a valve that keeps fluid from the brain flowing in the right direction, at the proper rate.

Companies in the US hydrocephalus shunts market are introducing new advanced programmable valves, shunts based on the latest technologies, and anti-siphon devices, among others. In May 2021, researchers at the Pennsylvania State University established the startup named Cranial Devices Inc. HydroFix, an advanced surgical shunt system designed by this company, provides a durable solution for normal pressure hydrocephalus (NPH) patients, along with mitigating risks associated with currently existing shunts. They have also applied for a license for the HydroFix technology from the Pennsylvania State University. In 2020, researchers at MIT proposed a shunt design to overcome the clogging of hydrocephalus catheters by leveraging catheter geometry.

The hydrocephalus shunts market in the US is expected to grow from US$ 109.61 million in 2022 to US$ 146.24 million by 2030; it is expected to grow at a CAGR of 3.7% from 2022 to 2030. Hydrocephalus is a prime cause of morbidity worldwide, and it is estimated to affect ~1 million people in the US, with an approximate incidence of 0.2–0.8 per 1000 live births. According to the National Institute of Neurological Disorders and Stroke (NINDS), hydrocephalus is assumed to affect ~1–2 in every 1,000 children born in the US. As per the University of California, Los Angeles Health Organization Approximately 125,000 people in the U.S. are currently living with cerebrospinal fluid shunts.

The majority of hydrocephalus cases are often diagnosed before birth, at the time of delivery, or in early childhood. The US hospitals discharge approximately 69,000 patients annually with a primary diagnosis of hydrocephalus, of which half undergo placement of a new shunt. Over half of these admissions were classified as emergent or urgent, and the average cost OF treatment was found to be US$ 35,816 each. The article published by Ausmed entitled “Hydrocephalus and Shunts” estimates that 33,000 people have shunts placed every year in US CSF diversion surgery and shunt revision surgery account for nearly one-third of all neurosurgical procedures annually in the country.

According to a study titled “Management of Hydrocephalus in Children: Anatomic Imaging Appearances of CSF Shunts and Their Complications,” published in the American Journal of Roentgenology in 2020, hydrocephalus affects approximately 1–2% of the US population and results in 70,000 hospitalizations, with the placement of 18,000–33,000 CSF shunts, and annual healthcare expenditures in the country is approximately US$ 2 billion.

In July 2023, Anuncia Medical Inc. announced the successful commercial launch of the ReFlow Mini Flusher device in the US. The ReFlow System Mini is a platform developed to enhance the function of CSF management devices in operating rooms, intensive care units, and homes. The US FDA has cleared ReFlow System Mini and ReFlow Mini Flusher under 510(k) for use in the treatment of hydrocephalus as part of a CSF shunt system. In 2020, researchers at MIT proposed a design to overcome the clogging of hydrocephalus catheters by leveraging catheter geometry.

B. Braun SE, Sophysa SA, Integra LifeSciences Holdings Corp, KANEKA MEDIX CORP, Medtronic Plc,      Natus Medical Inc, Anuncia Inc, Desu Medical are the leading companies in the US hydrocephalus shunts market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com